Your browser doesn't support javascript.
loading
Phase 1 study of C-CAR088, a novel humanized anti-BCMA CAR T-cell therapy in relapsed/refractory multiple myeloma.
Qu, Xiaoyan; An, Gang; Sui, Weiwei; Wang, Tingyu; Zhang, Xian; Yang, Junfang; Zhang, Yan; Zhang, Lu; Zhu, Dan; Huang, Jiaqi; Zhu, Shigui; Yao, Xin; Li, Jing; Zheng, Chengxiao; Zhu, Kevin; Wei, Yutian; Lv, Xiaoteng; Lan, Liping; Yao, Yihong; Zhou, Daobin; Lu, Peihua; Qiu, Lugui; Li, Jianyong.
Afiliación
  • Qu X; Department of Hematology, First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing, China.
  • An G; State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China.
  • Sui W; State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China.
  • Wang T; State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China.
  • Zhang X; Department of hematology, Hebei Yanda Lu Daopei Hospital, Langfang, China.
  • Yang J; Department of hematology, Hebei Yanda Lu Daopei Hospital, Langfang, China.
  • Zhang Y; Department of hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.
  • Zhang L; Department of hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.
  • Zhu D; Cellular Biomedicine Group Inc, Shanghai, China.
  • Huang J; Cellular Biomedicine Group Inc, Shanghai, China.
  • Zhu S; Cellular Biomedicine Group Inc, Shanghai, China.
  • Yao X; Cellular Biomedicine Group Inc, Shanghai, China.
  • Li J; Cellular Biomedicine Group Inc, Shanghai, China.
  • Zheng C; Cellular Biomedicine Group Inc, Shanghai, China.
  • Zhu K; University of Maryland School of Medicine, Baltimore, Maryland, USA.
  • Wei Y; Cellular Biomedicine Group Inc, Shanghai, China.
  • Lv X; Cellular Biomedicine Group Inc, Shanghai, China.
  • Lan L; Cellular Biomedicine Group Inc, Shanghai, China.
  • Yao Y; Cellular Biomedicine Group Inc, Shanghai, China.
  • Zhou D; Department of hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.
  • Lu P; Department of hematology, Hebei Yanda Lu Daopei Hospital, Langfang, China.
  • Qiu L; State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China.
  • Li J; Department of Hematology, First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing, China lijianyonglm@126.com.
J Immunother Cancer ; 10(9)2022 09.
Article en En | MEDLINE | ID: mdl-36100310
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Receptores Quiméricos de Antígenos / Mieloma Múltiple Límite: Humans Idioma: En Revista: J Immunother Cancer Año: 2022 Tipo del documento: Article País de afiliación: China
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Receptores Quiméricos de Antígenos / Mieloma Múltiple Límite: Humans Idioma: En Revista: J Immunother Cancer Año: 2022 Tipo del documento: Article País de afiliación: China